Zandoriah

CinnaGen has secured its first EU authorization for Zandoriah®, a Teriparatide biosimilar for osteoporosis, approved by the European Commission. This marks a significant market entry across 30 EEA states, leveraging CinnaGen's manufacturing investments. Decision-makers must assess new supply chain opportunities and competitive shifts in the European bone health market.

CinnaGen has secured European Commission approval for Zandoriah, its teriparatide biosimilar for osteoporosis, across all 30 EEA states. This pivotal regulatory milestone introduces a new, cost-effective treatment option, intensifying competition in the European osteoporosis market. Procurement directors must re-evaluate sourcing strategies, while regulatory affairs heads should note the EMA-compliant biosimilarity precedent. This approval signals significant shifts for supply chain and business development executives in the region.